Regulation of stathmin phosphorylation in mouse liver progenitor (MLP-29) cells during proteasome inhibition
Santamaría E, Mora MI, Muñoz J, Sánchez-Quiles V, Fernández-Irigoyen J, Prieto J, Corrales FJ.
Center for Applied Medical Research (CIMA). University of Navarra. Proteomics Laboratory. 31008 Pamplona, Spain
Proteasome inhibitors are potential therapeutic agents in the treatment of hepatocarcinoma and other liver diseases.
The analysis of alternative protein phosphorylation states might contribute to elucidate the underlying mechanisms of proteasome inhibitor-induced apoptosis. We have investigated the response of MLP-29 cells to MG132 using a combination of phosphoprotein affinity chromatography, Differential in Gel Electrophoresis (DIGE), and nanoLC-MS/MS. Thirteen unique deregulated phosphoproteins involved in chaperone activity, stress response, mRNA processing and cell cycle control were unambiguously identified. Alterations in NDRG1, and stathmin suggest new mechanisms associated to proteasome inhibitor-induced apoptosis in MLP-29 cells. Particularly, a transient modification of the phosphorylation state of Ser(16), Ser(25) and Ser(38), which are involved in the regulation of stathmin activity, was detected in three distinct isoforms upon proteasome inhibition.
The parallel deregulation of calcium/calmodulin-activated protein kinase II (CaMKII), extracellular regulated kinase (ERK1/2) and cyclin-dependent kinase (CDK2), might explain the modified phosphorylation pattern of stathmin. Interestingly, stathmin phosphorylation profile was also modified in response to epoxomicin treatment, a more specific proteasome inhibitor. In summary, we report here data supporting that regulation of NDRG1 and stathmin by phosphorylation at specific Ser/Thr residues may participate in the cellular response induced by proteasome inhibitors.
CITA DEL ARTÍCULO Proteomics. 2009 Oct;9(19):4495-506